Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS · Delayed Price · Currency is USD
23.83
-1.53 (-6.03%)
Oct 31, 2025, 4:00 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
$676,540
Profits / Employee
$95,691
Market Cap
44.06B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | 16,033 | 685 | 4.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Daiichi Sankyo Company News
- 2 days ago - Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results - GuruFocus
- 2 days ago - Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook - Seeking Alpha
- 2 days ago - Daiichi Sankyo Company, Limited 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down - Nasdaq
- 3 days ago - Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect - GuruFocus
- 12 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript - Seeking Alpha
- 12 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions - Slideshow - Seeking Alpha
- 20 days ago - Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO - Business Wire